Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR6390 plus non-steroidal aromatase inhibitors in ER-positive recurrent/metastatic ovarian and uterine tumors
ChiCTR2000040597Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib, letrozole, anastrozole and goserelin in ovarian cancer, uterine cancer, endometrial cancer (EC) and 3 more, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 12-week progression-free survival rate. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
dalpiciclibletrozoleanastrozolegoserelin
03
Conditions
ovarian canceruterine cancerendometrial cancer (EC)Endometrial Sarcoma (ESS)uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on ChiCTR2000040597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040597.